SEMA3A and pancreatic neuroendocrine tumor: In mouse models of pancreatic neuroendocrine tumors and cervical carcinoma, the expression of Sema3A overcomes proinvasive and prometastatic resistance [51], while the knockdown of Sema3A increased the sensitivity of Lewis lung cancer cells to EGFR-TKIs gefitinib and erlotinib [52].